Childhood Cancer Data Initiative Annual Symposium (Abstract Registration): Submission #52

Submission information
Submission Number: 52
Submission ID: 150414
Submission UUID: bad92d7a-0903-422c-a3b5-bc5a5c81a41f

Created: Fri, 08/29/2025 - 17:37
Completed: Fri, 08/29/2025 - 17:40
Changed: Fri, 08/29/2025 - 17:40

Remote IP address: 10.208.28.51
Submitted by: Anonymous
Language: English

Is draft: No
Abstract Title: The Children’s Oncology Group and Alex’s Lemonade Stand Foundation Childhood Cancer Repository
Abstract: The Children’s Oncology Group (COG) childhood cancer repository (www.CCcells.org), supported by ALSF, establishes, validates, and banks patient-derived cell lines (PDCLs) and patient-derived xenografts (PDXs) from childhood cancers. Viable tumor, blood, or bone marrow samples obtained under informed consent via COG protocols are sent to a centralized resource lab to establish PDCLs and PDXs. PDCLs/PDXs are validated by short tandem repeat assay to patient material, verified free of human and mouse pathogens, tumor type validated by biomarkers, and telomere maintenance mechanism assessed. The repository has available PDCLs/PDXs from 560/85 neuroblastomas, 16/20 leukemias, 7/5 lymphomas, 20/3 Ewing sarcomas, 13/3 soft tissue sarcomas. 32/1 retinoblastomas, 1/2 osteosarcomas, 2/5 Wilm’s tumors, and 11 PDCLs from brain tumors. Hypoxic culture conditions are used to establish PDCLs, enhancing success rates and minimizing selection against cells by hyperoxia. Small samples more often are able to generate a PDCL and we have demonstrated comparability of low-passage hypoxia PDCLs to generate xenografts comparable in RNA expression and drug response profiles to PDXs. Neuroblastoma PDCLs and PDXs are being established from patients enrolled on COG phase III studies at diagnosis and from disease persisting or progressing during and after therapy to enable future studies comparing genomics and drug response of PDCLs and PDXs to patient data. To date 58 PDCLs and 17 PDXs have been established from patients on the ANBL1531 phase III trial and PDCLs/PDXs from 30 patients on the ANBL2131 phase III study. The repository distributes PDCLs and PDXs to > 500 laboratories in 30 countries.
Abstract:
Authors:
  1. First Name: C Patrick
    Last Name: Reynolds
    Degree(s): MD PhD
    Organization: Texas Tech University Health Sciences Center School of Medicine Lubbock, TX
  2. First Name: Kristyn
    Last Name: McCoy
    Degree(s): MS
    Organization: Texas Tech University Health Sciences Center School of Medicine Lubbock, TX
  3. First Name: Diana
    Last Name: Ixlamati-Nava
    Degree(s): BS
    Organization: Texas Tech University Health Sciences Center School of Medicine Lubbock, TX
  4. First Name: Jonas
    Last Name: Nance
    Degree(s): BS
    Organization: Texas Tech University Health Sciences Center School of Medicine Lubbock, TX
  5. First Name: Balakrishna
    Last Name: Koneru
    Degree(s): PhD
    Organization: Texas Tech University Health Sciences Center School of Medicine Lubbock, TX
  6. First Name: Min
    Middle Initial: H
    Last Name: Kang
    Degree(s): PharmD
    Organization: Texas Tech University Health Sciences Center School of Medicine Lubbock, TX
Presenting Author: C Patrick Reynolds
Institution: Texas Tech University Health Sciences Center School of Medicine Lubbock, TX
Email Address: patrick.reynolds@ttuhsc.edu